GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CellSource Co Ltd (TSE:4880) » Definitions » EBITDA Margin %

CellSource Co (TSE:4880) EBITDA Margin % : 18.16% (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CellSource Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. CellSource Co's EBITDA for the three months ended in Jan. 2024 was 円213 Mil. CellSource Co's Revenue for the three months ended in Jan. 2024 was 円1,174 Mil. Therefore, CellSource Co's EBITDA margin for the quarter that ended in Jan. 2024 was 18.16%.


CellSource Co EBITDA Margin % Historical Data

The historical data trend for CellSource Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellSource Co EBITDA Margin % Chart

CellSource Co Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
EBITDA Margin %
Get a 7-Day Free Trial 20.11 23.68 35.49 38.12 28.91

CellSource Co Quarterly Data
Oct18 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.05 28.73 34.46 14.08 18.16

Competitive Comparison of CellSource Co's EBITDA Margin %

For the Biotechnology subindustry, CellSource Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellSource Co's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CellSource Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where CellSource Co's EBITDA Margin % falls into.



CellSource Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

CellSource Co's EBITDA Margin % for the fiscal year that ended in Oct. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Oct. 2023 )/Revenue (A: Oct. 2023 )
=1303.912/4510.544
=28.91 %

CellSource Co's EBITDA Margin % for the quarter that ended in Jan. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jan. 2024 )/Revenue (Q: Jan. 2024 )
=213.087/1173.516
=18.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CellSource Co  (TSE:4880) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


CellSource Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of CellSource Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


CellSource Co (TSE:4880) Business Description

Traded in Other Exchanges
N/A
Address
Shibuya Mitake Building, 2nd Floor, 1-19-5 Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.

CellSource Co (TSE:4880) Headlines

No Headlines